Safety and management of niraparib monotherapy in ovarian cancer clinical trials

Niraparib is a poly (ADP-ribose) polymerase inhibitor that has shown a significant improvement in progression-free survival irrespective of biomarker status in patients with advanced epithelial ovarian cancer. This review focuses on the adverse events associated with niraparib and their management t...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J, González-Martin, Antonio, Buckley, Lynn, Matulonis, Ursula A., Rimel, B J, Wu, Xiaohua, Moore, Kathleen N, Mirza, Mansoor R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313963/
https://www.ncbi.nlm.nih.gov/pubmed/36792166
http://dx.doi.org/10.1136/ijgc-2022-004079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313963/
https://www.ncbi.nlm.nih.gov/pubmed/36792166
http://dx.doi.org/10.1136/ijgc-2022-004079

Ejemplares similares